Learn About Multiple Endocrine Neoplasia Type 2

View Main Condition: Neural Crest Tumor

What is the definition of Multiple Endocrine Neoplasia Type 2?

Multiple endocrine neoplasia, type II (MEN II) is a disorder passed down through families in which one or more of the endocrine glands are overactive or form a tumor. Endocrine glands most commonly involved include:

  • Adrenal gland (about half the time)
  • Parathyroid gland (20% of the time)
  • Thyroid gland (almost all the time)

Multiple endocrine neoplasia, type I (MEN I) is a related condition.

Save information for later
Sign Up
What are the alternative names for Multiple Endocrine Neoplasia Type 2?

Sipple syndrome; MEN II; Pheochromocytoma - MEN II; Thyroid cancer - pheochromocytoma; Parathyroid cancer - pheochromocytoma

What are the causes of Multiple Endocrine Neoplasia Type 2?

The cause of MEN II is a defect in a gene called RET. This defect causes many tumors to appear in the same person, but not necessarily at the same time.

Involvement of the adrenal gland is most often with a tumor called a pheochromocytoma.

Involvement of the thyroid gland is most often with a tumor called medullary carcinoma of the thyroid.

Tumors in the thyroid, adrenal, or parathyroid glands may occur years apart.

The disorder may occur at any age, and affects men and women equally. The main risk factor is a family history of MEN II.

There are two subtypes of MEN II. They are MEN IIa and IIb. MEN IIb is less common.

What are the symptoms of Multiple Endocrine Neoplasia Type 2?

The symptoms may vary. However, they are similar to those of:

  • Medullary carcinoma of the thyroid
  • Pheochromocytoma
  • Parathyroid adenoma
  • Parathyroid hyperplasia
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Multiple Endocrine Neoplasia Type 2?

Surgery is needed to remove a pheochromocytoma, which can be life threatening due to the hormones it makes.

For medullary carcinoma of the thyroid, the thyroid gland and surrounding lymph nodes must be totally removed. Thyroid hormone replacement therapy is given after surgery.

If a child is known to carry the RET gene mutation, surgery to remove the thyroid before it becomes cancerous is considered. This should be discussed with a physician who is very familiar with this condition. It would be done at an early age (before age 5) in people with known MEN IIa, and before age 6 months in people with MEN IIb.

Who are the top Multiple Endocrine Neoplasia Type 2 Local Doctors?
Elite
Elite
 
 
 
 
Learn about our expert tiers
Learn more
Elite
What is the outlook (prognosis) for Multiple Endocrine Neoplasia Type 2?

Pheochromocytoma is most often not cancerous (benign). Medullary carcinoma of the thyroid is a very aggressive and potentially fatal cancer, but early diagnosis and surgery can often lead to a cure. Surgery does not cure the underlying MEN II.

What are the possible complications of Multiple Endocrine Neoplasia Type 2?

The spread of cancerous cells is a possible complication.

When should I contact a medical professional for Multiple Endocrine Neoplasia Type 2?

Contact your provider if you notice symptoms of MEN II or if someone in your family receives such a diagnosis.

How do I prevent Multiple Endocrine Neoplasia Type 2?

Screening close relatives of people with MEN II may lead to early detection of the syndrome and related cancers. This may allow for steps to prevent complications.

Endocrine glands
What are the latest Multiple Endocrine Neoplasia Type 2 Clinical Trials?
Familial Investigations of Childhood Cancer Predisposition

Summary: NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Coordination of Rare Diseases at Sanford

Summary: CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, in...

What are the Latest Advances for Multiple Endocrine Neoplasia Type 2?
Management of carotid artery stenosis.
Tired of the same old research?
Check Latest Advances
Medullary thyroid carcinoma: current clinical progress.
Who are the sources who wrote this article ?

Published Date: January 25, 2022
Published By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

What are the references for this article ?

National Comprehensive Cancer Network website. Clinical practice guidelines in oncology (NCCN guidelines): neuroendocrine and adrenal tumors. Version 1.2022. www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Updated May 23, 2022. Accessed August 23, 2022.

Newey PJ, Thakker RV. Multiple endocrine neoplasia. In: Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, Rosen CJ, eds. Williams Textbook of Endocrinology. 14th ed. Philadelphia, PA: Elsevier; 2020:chap 42.

Nieman LK, Spiegel AM. Polyglandular disorders. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 218.

Tacon LJ, Learoyd DL, Robinson BG. Multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. In: Jameson JL, De Groot LJ, de Kretser DM, et al, eds. Endocrinology: Adult and Pediatric. 7th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 149.